COMMUNIQUÉS West-GlobeNewswire

DBV Technologies participera à la 47ème conférence annuelle Global Healthcare organisée par Goldman Sachs
05/06/2026
Châtillon, France, le 5 juin (22 :30 CEST) 2026 DBV Technologies participera à la 47 ème conférence annuelle Global Healthcare organisée par Goldman Sachs DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq [...]
Spyre Therapeutics Announces Grants of Inducement Awards
05/06/2026
WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/06/2026
WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
HRC Technology Solutions LLC Expands Scope and Is Successfully Reappraised at CMMI® Services Maturity Level 3, Reinforcing Its AI-Driven Operating Model
05/06/2026
SOUTHLAKE, Texas, June 05, 2026 (GLOBE NEWSWIRE) -- HRC Technology Solutions LLC, a leading technology-enabled Revenue Cycle Management (RCM) solutions provider to U.S. healthcare organizations, today announced that its [...]
Premier Health of America Announces Grant of Management Cease Trade Order
05/06/2026
MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“Premier Health” , or the “Company” ) announces that, further to its press release dated June 2, 2026, the Autorité des marchés [...]
Nyxoah Annonce la Fixation du Prix de l'Offre Publique Souscrite de 95 millions $
05/06/2026
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES Nyxoah Annonce la Fixation du Prix de l'Offre Publique Souscrite de 95 millions $ Mont-Saint-Guibert, Belgique – 5 juin 2026, 17h25 CET / 11h25 ET - Nyxoah SA ( [...]
Memo Therapeutics AG Presents Further Analyses of the Phase II Trial Results of Potravitug for the Treatment of BKPyV Infection in Kidney Transplant Recipients in an Oral Presentation at the 63rd European Renal Association Congress
05/06/2026
PRESS RELEASE First-in-class therapeutic antibody, potravitug, for BK polyomavirus infection showed consistent reduction in viral load and biopsy-proven BKPyVAN in a Phase II study in kidney transplant recipients [...]
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
05/06/2026
New real-world survey data reveal the daily impact of Huntington’s disease (HD) chorea, with over 68% of patients reporting interference with social life or emotional wellbeing 1 and up to 83% of caregivers noting [...]
Vivex Biologics Publishes New Medicare Real-World Evidence Study Showing VIA Disc® NP Significantly Reduces Opioid Use, Imaging, and Conservative Care Utilization in Patients with Lumbar Discogenic Pain
05/06/2026
Analysis of 1,804 Medicare beneficiaries per group demonstrates a meaningful shift in the continuum of care following intradiscal nucleus pulposus allograft procedure MIAMI, June 05, 2026 (GLOBE NEWSWIRE) -- Vivex [...]
EnGeneIC Honored with 2026 Breakthrough in Glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York
05/06/2026
SYDNEY and NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- EnGeneIC Limited today announced it has been recognized with the Breakthrough in glioblastoma Biotech Award 2026 at the Northwell Foundation, Lenox Hill [...]
Victoire : un projet de loi vise à encadrer la vente des boissons énergisantes caféinées aux jeunes de moins de 16 ans
05/06/2026
MONTRÉAL, 05 juin 2026 (GLOBE NEWSWIRE) -- Cœur + AVC et le Collectif Vital applaudissent le dépôt du projet de loi 9, Loi visant à prévenir les effets nocifs de la boisson énergisante sur la santé des jeunes , ou [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
05/06/2026
Nantes, le 5 juin 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), une société de [...]
Nyxoah Announces Pricing of $95 Million Underwritten Public Offering
05/06/2026
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Pricing of $95 Million Underwritten Public Offering Mont-Saint-Guibert, Belgium – June 5, 2026, 5:25 pm CET / 11:25 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: [...]
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/06/2026
STOUGHTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it awarded inducement grants on June 1, 2026 under the Company's 2026 Inducement Plan (the 2026 [...]
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/06/2026
PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™
05/06/2026
Kennewick, WA, June 05, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a company pioneering Precision Radionuclide Therapy ™ (PRnT) with its innovative RadioGel ® technology, today announced the submission of its [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05/06/2026
DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
Eos SENOLYTIX Presents Best-in-Class Preclinical Body Composition Data Highlighting Unique Muscle Mass Gains with MitoXcel™ Geropeptide PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum
05/06/2026
Multi-System Improvements in Healthspan with PTC-2105 Treatment Translate into Associated Significant Increases in Cancer-Specific and Overall Survival HOUSTON, June 05, 2026 (GLOBE NEWSWIRE) -- Eos SENOLYTIX, Inc. (“ [...]
FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF
05/06/2026
SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today [...]

Pages